StemCell Therapy

The Global Ship-to-Shore (STS) Container Cranes Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=211979

The Global Ship-to-Shore (STS) Container Cranes Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Ship-to-Shore (STS) Container Cranes Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Ship-to-Shore (STS) Container Cranes Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=211979

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Ship-to-Shore (STS) Container Cranes Market as:Global Ship-to-Shore (STS) Container Cranes Market Size & Share, by Regions

Global Ship-to-Shore (STS) Container Cranes Market Size & Share, by ProductsRated Loading Capacity: 65tonRated Loading Capacity: 80tonRated Loading Capacity: 120tonOther

Global Ship-to-Shore (STS) Container Cranes Market Size & Share, ApplicationsSea & River TransportationQuay Transportation

Key PlayersLiebherrSANYTerexKonecranesZPMCGantrexKalmarglobalBaltkranWeihua Group

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=211979

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Read more here:
How Ship-to-Shore (STS) Container Cranes Market Will Dominate In Coming Years? Report Covering Products, Financial Information, Developments, Swot...

This report studies theAugmented Reality(AR) and Virtual Reality(VR) In Gamingmarket with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the completeAugmented Reality(AR) and Virtual Reality(VR) In Gamingmarket analysis segmented by companies, region, type and applications in the report.

New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

The key players covered in this study: Niantic, Sony, Valve, Ubisoft, Next Games, Ludia Inc, Six To Start, esDot

The final report will add the analysis of the Impact of Covid-19 in this report Augmented Reality(AR) and Virtual Reality(VR) In Gaming industry.

Get a Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-augmented-reality-ar-and-virtual-reality-vr-in-gaming-market-size-status-and-forecast-2020-2026

Augmented Reality(AR) and Virtual Reality(VR) In GamingMarket in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting. A Augmented Reality(AR) and Virtual Reality(VR) In Gaming Market provides an extensive view of size; trends and shape have been developed in this report to identify factors that will exhibit a significant impact in boosting the sales of Augmented Reality(AR) and Virtual Reality(VR) In Gaming Market in the near future.

This report focuses on the global Augmented Reality(AR) and Virtual Reality(VR) In Gaming status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Augmented Reality(AR) and Virtual Reality(VR) In Gaming development inUnitedStates, Europe, China, Japan, Southeast Asia, India, and Central & South America.

Market segment by Type, the product can be split into

Market segment by Application, split into

TheAugmented Reality(AR) and Virtual Reality(VR) In Gamingmarket is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Augmented Reality(AR) and Virtual Reality(VR) In Gaming Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

Research objectives:

Inquire More about This Report @https://www.reportsandmarkets.com/enquiry/global-augmented-reality-ar-and-virtual-reality-vr-in-gaming-market-size-status-and-forecast-2020-2026

TheAugmented Reality(AR) and Virtual Reality(VR) In Gamingmarket research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents

Chapter 1:GlobalAugmented Reality(AR) and Virtual Reality(VR) In GamingMarket Overview

Chapter 2:Augmented Reality(AR) and Virtual Reality(VR) In Gaming Market Data Analysis

Chapter 3:Augmented Reality(AR) and Virtual Reality(VR) In Gaming Technical Data Analysis

Chapter 4:Augmented Reality(AR) and Virtual Reality(VR) In Gaming Government Policy and News

Chapter 5:Global Augmented Reality(AR) and Virtual Reality(VR) In Gaming Market Manufacturing Process and Cost Structure

Chapter 6:Augmented Reality(AR) and Virtual Reality(VR) In Gaming Productions Supply Sales Demand Market Status and Forecast

Chapter 7:Augmented Reality(AR) and Virtual Reality(VR) In Gaming Key Manufacturers

Chapter 8:Up and Down Stream Industry Analysis

Chapter 9:Marketing Strategy -Augmented Reality(AR) and Virtual Reality(VR) In Gaming Analysis

Chapter 10:Augmented Reality(AR) and Virtual Reality(VR) In Gaming Development Trend Analysis

Chapter 11:Global Augmented Reality(AR) and Virtual Reality(VR) In Gaming Market New Project Investment Feasibility Analysis

About Us:

Reports and Marketsis not just another company in this domain but is a part of a veteran group calledAlgoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the original post:
AUGMENTED REALITY(AR) AND VIRTUAL REALITY(VR) IN GAMING MARKET 2020 BY TRENDS ANALYSIS, BY PRODUCT USABILITY PROFILES, BY FORECASTS TO 2026 - Bulletin...

Yuan Hong,1 Shaomin Che,2 Beina Hui,2 Xiaoli Wang,2 Xiaozhi Zhang,2 Hailin Ma2

1Department of Medical Imaging, The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, Peoples Republic of China; 2Department of Oncology Radiotherapy, The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, Peoples Republic of China

Correspondence: Hailin MaDepartment of Oncology Radiotherapy, The First Affiliated Hospital of Xian Jiaotong University, No. 277 Yanta Xi Road, Xian, Shaanxi 710061, Peoples Republic of ChinaEmail mahlxjtu@sohu.com

Purpose: Lung cancer remains the leading cancer-associated deaths worldwide. Cisplatin (CDDP) was used in combination with curcumin (CUR) for the treatment of non-small cell lung cancer. The aim of this study was to prepare and characterize CDDP prodrug and CUR co-encapsulated layer-by-layer nanoparticles (CDDP-PLGA/CUR LBL NPs) to induce cooperative response, maximize the therapeutic effect, overcome drug resistance, and reduce adverse side effects.Methods: CDDP prodrug (CDDP-PLGA) was synthesized. CDDP-PLGA/CUR LBL NPs were constructed and their physicochemical properties were investigated by particle-size analysis, zeta potential measurement, drug loading, drug entrapment efficiency, and in vitro drug release behavior. In vitro cytotoxicity against human lung adenocarcinoma cell line (A549 cells) was investigated, and in vivo anti-tumor efficiency of CDDP-PLGA/CUR LBL NPs was evaluated on mice bearing A549 cell xenografts.Results: CDDP-PLGA/CUR LBL NPs have a size of 179.6 6.7 nm, a zeta potential value of 29.9 3.2 mV, high drug entrapment efficiency of 85.6 3.9% (CDDP) and 82.1 2.8% (CUR). The drug release of LBL NPs exhibited a sustained behavior, which made it an ideal vehicle for drug delivery. Furthermore, CDDP-PLGA/CUR LBL NPs could significantly enhance in vitro cytotoxicity and in vivo antitumor effect against A549 cells and lung cancer animal model compared to the single drug-loaded LBL NPs and free drug groups.Conclusion: CDDP-PLGA/CUR LBL NPs were reported for the first time in the combination therapy of lung cancer. The results demonstrated that the CDDP-PLGA/CUR LBL NPs might be a novel promising system for the synergetic treatment of lung carcinoma.

Keywords: lung cancer, combination therapy, layer-by-layer, cisplatin prodrug, curcumin

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More here:
Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prod | DDDT - Dove Medical Press

EVERGREEN, Colo., June 9, 2020 (SEND2PRESS NEWSWIRE) Combining the use of Eastern and Western philosophy of Holistic Medicine, Dr. Christina Fick, of Evergreen Medical Acupuncture, has created a carefully selected offering of CGMP (certified good manufacturing practice), and organic certified supplements and herbal products that provide a well-balanced approach to healing.

Evergreen Medical Acupuncture, a locally owned and operated Colorado Business located in Evergreen, Colorado, has always offered the best of Eastern and Western Medicine to its customers, and is happy to announce the new online store for these offering, Dr. Ficks Functional Farmacy, at https://www.drchristinafick.com/functional-farmacy.

With a wide variety of hand-picked, quality herbal supplements with a focus on some of the best practices of Eastern Medicine, Dr. Ficks Functional Farmacy provides clients the ease of online information and recommendations, and the ability to order products from home. Products such as Phyto-Multiplex, a multi-vitamin + phytonutrient + trace mineral supplement, Premium Choline for brain, gut, and general health, and Nutra-Absorb for digestive support, are now ready for the online audience.

Dr. Ficks Functional Farmacy is also offering an exclusive cosmetic line, Skin for Life, and a selection of specialty luxury soaps, called My Soap Box. Skin for Lifes ingredient formulas are in a nutritional nano bio-emulsion sphere that delivers vitamins, minerals, and essential lipids to protect the skins immunity integrity, and the beautifully scented, exotic body and facial bar soaps of My Soap Box are a perfect way to provide an escape from the days stresses, or to provide a truly unique gift for someone dear to you.

We offer the best of Eastern and Western Medicine to our clients The Chinese now see the benefit of modern medicine, and how it can be applied to the practice of Traditional Chinese Medicine, stated Dr. Christina Fick. By combining the best of both worlds, we can achieve sustainable results for our clients using Acupuncture, Specialty Needle Techniques, and our custom-built Acupuncture Clinic. These herbal supplements and new products represent some of our best recommendations, and compliment these techniques, and are now available to clients with a mouse-click.

About Evergreen Medical Acupuncture, Dr. Ficks Functional Farmacy, and Dr. Christina Fick

Located in both Evergreen, Colorado, Evergreen Medical Acupuncture is locally owned and operated. The company and its employees live and work in Colorado, and also offer phone or video chat appointments for consultation to anyone in the nation. The acupuncturists on in the Clinic work closely under Dr. Fick, have been hand-selected and vetted, and go through rigorous ongoing training to provide highest standards of service and customer care.

Dr. Christina Fick is the owner and founder of Evergreen Medical Acupuncture, LLC, first opened in 2012. She holds a Doctorate in Acupuncture and Oriental Medicine, a Masters degree in Herbology, and is certified in Functional Medicine. She has worked globally in her specialized field, in hospitals both in China, and in New York.

For more information about Dr. Ficks Functional Farmacy, and Evergreen Medical Acupuncture, including details about their services and new custom built Acupuncture Clinic, please visit the company website: https://www.drchristinafick.com/, or call to book an appointment or learn more at 303-594-8348.

*PHOTO link for media: https://www.Send2Press.com/300dpi/20-0609s2p-evergreen-med-300dpi.jpg

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

News Source: Evergreen Medical Chiropractic and Acupuncture

To view the original post, visit: https://www.send2press.com/wire/evergreen-medical-acupuncture-is-now-offering-its-own-supplement-and-herbal-products-dr-ficks-functional-farmacy/.

This press release was issued by Send2Press Newswire on behalf of the news source, who is solely responsible for its accuracy. http://www.send2press.com.

Go here to read the rest:
Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY

A new market report by Market Research Intellect on the Nanomedicine Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Nanomedicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=201321&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Nanomedicine manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Nanomedicine Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201321&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Nanomedicine. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=201321&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Nanomedicine market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the rest here:
Nanomedicine Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

Nanomedicine is one of the applications of nanotechnology used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine uses nanoscale manipulation of materials to improve medicine delivery. Thus, nanomedicine has facilitated the treatment against various diseases. Nanomedicine is in nascent stage, as several products are in the development phase. According to Nanobiotix (a nanomedicine company), in 2015, around 230 nanomedicine products were identified, which are either marked or are in the trial phase.

Get the PDF Sample Copy of this Report:

https://www.a2zmarketresearch.com/sample?reportId=20562

This report covers Nanomedicines market from the bottom line, starting from its definition. Later, it segments the market on various criteria to give a depth of understanding on the various product types and pricing structures and applications. Each and every segment is examined carefully by factoring in sales, revenue and market size in order to understand the potential of growth and scope.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Nanomedicines market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Nanomedicines markets trajectory between forecast periods.

Some of the Top Companies Profiled in this Market includes:

Global Nanomedicines Market Segmentation:

Market Segmentation: By Product

Market Segmentation: By Nanomolecule Type

Market Segmentation: By Application

Get Special Discount Upto 30% on this Report:

https://www.a2zmarketresearch.com/discount?reportId=20562

Key questions answered in the report include:

Table of Contents

Global Nanomedicines Market Research Report

Chapter 1 Nanomedicines Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Nanomedicines Market Forecast

Buy Exclusive Research Report:

https://www.a2zmarketresearch.com/buy?reportId=20562

If you have any special requirements, please let us know and we will offer you the report as you want.

Follow this link:
Nanomedicines Market will touch a new level in upcoming year with Top Key Players like Abbott, GE Healthcare, Johnson & Johnson, Merck, Pfizer,...

Products

Marketing Statements

CBD Products

CBD products

CBD products

CBD products

CBD products

CBD products

CBD products

CBD products

Dietary Supplements and Vitamins

Vitamin C product

Vitamin D products

Super C, Vitamin D/K2, Zinc Charge, and Immuno-Strong Berry Liquid

NoronaPak products, including supplement products

Dietary supplements

Grapefruit seed extract, colostrum, and cod liver oil products

Essential Oils

Essential oils and dietary supplements

Essential oil products

Essential oil products

Essential oil products

Essential oil products

Essential oil products

Essential oil products

Essential oils and herbal products

Herbal Products

Herbal products

Herbal products

Herbal products

Herbal tinctures and herbal remedy products

Herbal products including CoronaDefender Herbal Sachet-S

Herbal products, including Carahealth Immune

Coronavirus Protocol (Coronavirus Boneset Tea, Coronavirus Cell Protection, Coronavirus Core tincture, Coronavirus Immune System, and Elderberry Tincture)

Formula #1, Formula #2, Formula #3, and Eupatorium perfoliatum (Boneset)

Homeopathic Products

Homeopathic Genus Epidemicus

Homeopathic drugs and dietary supplement products

Homeopathic drug products

Homeopathic drugs

Sanitizer/Antimicrobial Products

Non-alcohol based hand sanitizer product

Non-alcohol based sanitizer products

Prefense Hand Sanitizers

Germ Stopper products

Sani-Bar GK95 and Sani-Disc GK95D

Products labeled to contain Silver

Colloidal silver products

Colloidal silver products

Colloidal silver products

Products labeled to contain silver

Silver Sol Liquid and products labeled to contain silver

Quicksilver Liposomal Vitamin C w/ Liposomal, Jigsaw Magnesium With SRT, and products labeled to contain silver

Superblue Silver Immune Gargle, SuperSilver Whitening Toothpaste, SuperSilver Wound Dressing Gel and Superblue Fluoride Free Toothpaste

HealthMax Nano-Silver Liquid, Silver Biotics Silver Lozenges with Vitamin C, and Silver Biotics Silver Gel Ultimate Skin & Body Care (collectively, your silver products)

Colloidal silver, vitamins, minerals, herb oils, and a homeopathic drug product

Liquid Silver, Camu Camus Vitamin C, Vitaly C, Immunity Kit, Vitamin D3-K2, and Power Immune

Silver, CBD products, iodine, medicinal mushroom, selenium, zinc, vitamin C, vitamin D3, astragalus, and elderberry

Other Products

Miracle Mineral Solution (MMS) (chlorine dioxide)

Fortify Humic Beverage Concentrate and Electrify Fulvic Beverage Concentrate

Honey product, COVID-19 COUGH Syrup

Salt therapy products

FullerLifeC60

Viral Defense Tincture

Traditional Chinese medicine products

China Oral Nosode, described as AN330 CORONA VIRAL IMMUNE SUPPORT AND/OR ACTIVE RESPIRATORY INFECTION FOR ALL AGES

Kratom products

Ayurvedic products

nCoV19 spike protein vaccine

CORE and IMMUNE SHOT

Defend Patch

NAD+ and NMN sublingual gel products

Corona-Cure Coronavirus Infection Prevention Nasal Spray

Viral Protection Kits

Read this article:
How FDA Is Monitoring The COVID-19 Product Market - JD Supra

A new market report by Market Research Intellect on the Neuropathy Pain Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Neuropathy Pain Treatment sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=275286&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Neuropathy Pain Treatment manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Neuropathy Pain Treatment Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=275286&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Neuropathy Pain Treatment. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=275286&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Neuropathy Pain Treatment market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Follow this link:
Neuropathy Pain Treatment Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Peripheral Neuritis Treatment market. It informs readers about key trends and opportunities in the global Peripheral Neuritis Treatment market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Peripheral Neuritis Treatment market.

Key companies operating in the global Peripheral Neuritis Treatment market include , Pfizer, Depomed, Novartis, Biogen, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Bristol-Myers Squibb, Baxter Healthcare, Johnson & Johnson, Teva Pharmaceuticals Peripheral Neuritis Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1456206/global-peripheral-neuritis-treatment-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Peripheral Neuritis Treatment market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Peripheral Neuritis Treatment Market Segment By Type:

, Diabetic Peripheral Neuropathy (DPN), Chemotherapy-induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy (IPN), Others

Global Peripheral Neuritis Treatment Market Segment By Application:

, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Peripheral Neuritis Treatment market.

Key companies operating in the global Peripheral Neuritis Treatment market include , Pfizer, Depomed, Novartis, Biogen, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Bristol-Myers Squibb, Baxter Healthcare, Johnson & Johnson, Teva Pharmaceuticals Peripheral Neuritis Treatment

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1456206/global-peripheral-neuritis-treatment-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Peripheral Neuritis Treatment Revenue1.4 Market Analysis by Type 1.4.1 Global Peripheral Neuritis Treatment Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Diabetic Peripheral Neuropathy (DPN) 1.4.3 Chemotherapy-induced Peripheral Neuropathy (CIPN) 1.4.4 Idiopathic Peripheral Neuropathy (IPN) 1.4.5 Others1.5 Market by Application 1.5.1 Global Peripheral Neuritis Treatment Market Share by Application: 2020 VS 2026 1.5.2 Hospital Pharmacies 1.5.3 Retail Pharmacies 1.5.4 Online Pharmacies 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Peripheral Neuritis Treatment Market Perspective (2015-2026)2.2 Peripheral Neuritis Treatment Growth Trends by Regions 2.2.1 Peripheral Neuritis Treatment Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Peripheral Neuritis Treatment Historic Market Share by Regions (2015-2020) 2.2.3 Peripheral Neuritis Treatment Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Peripheral Neuritis Treatment Market Growth Strategy 2.3.6 Primary Interviews with Key Peripheral Neuritis Treatment Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Peripheral Neuritis Treatment Players by Market Size 3.1.1 Global Top Peripheral Neuritis Treatment Players by Revenue (2015-2020) 3.1.2 Global Peripheral Neuritis Treatment Revenue Market Share by Players (2015-2020) 3.1.3 Global Peripheral Neuritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Peripheral Neuritis Treatment Market Concentration Ratio 3.2.1 Global Peripheral Neuritis Treatment Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Peripheral Neuritis Treatment Revenue in 20193.3 Peripheral Neuritis Treatment Key Players Head office and Area Served3.4 Key Players Peripheral Neuritis Treatment Product Solution and Service3.5 Date of Enter into Peripheral Neuritis Treatment Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Peripheral Neuritis Treatment Historic Market Size by Type (2015-2020)4.2 Global Peripheral Neuritis Treatment Forecasted Market Size by Type (2021-2026) 5 Peripheral Neuritis Treatment Breakdown Data by Application (2015-2026)5.1 Global Peripheral Neuritis Treatment Market Size by Application (2015-2020)5.2 Global Peripheral Neuritis Treatment Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Peripheral Neuritis Treatment Market Size (2015-2020)6.2 Peripheral Neuritis Treatment Key Players in North America (2019-2020)6.3 North America Peripheral Neuritis Treatment Market Size by Type (2015-2020)6.4 North America Peripheral Neuritis Treatment Market Size by Application (2015-2020) 7 Europe7.1 Europe Peripheral Neuritis Treatment Market Size (2015-2020)7.2 Peripheral Neuritis Treatment Key Players in Europe (2019-2020)7.3 Europe Peripheral Neuritis Treatment Market Size by Type (2015-2020)7.4 Europe Peripheral Neuritis Treatment Market Size by Application (2015-2020) 8 China8.1 China Peripheral Neuritis Treatment Market Size (2015-2020)8.2 Peripheral Neuritis Treatment Key Players in China (2019-2020)8.3 China Peripheral Neuritis Treatment Market Size by Type (2015-2020)8.4 China Peripheral Neuritis Treatment Market Size by Application (2015-2020) 9 Japan9.1 Japan Peripheral Neuritis Treatment Market Size (2015-2020)9.2 Peripheral Neuritis Treatment Key Players in Japan (2019-2020)9.3 Japan Peripheral Neuritis Treatment Market Size by Type (2015-2020)9.4 Japan Peripheral Neuritis Treatment Market Size by Application (2015-2020) 10Key Players Profiles10.1 Pfizer 10.1.1 Pfizer Company Details 10.1.2 Pfizer Business Overview and Its Total Revenue 10.1.3 Pfizer Peripheral Neuritis Treatment Introduction 10.1.4 Pfizer Revenue in Peripheral Neuritis Treatment Business (2015-2020)) 10.1.5 Pfizer Recent Development10.2 Depomed 10.2.1 Depomed Company Details 10.2.2 Depomed Business Overview and Its Total Revenue 10.2.3 Depomed Peripheral Neuritis Treatment Introduction 10.2.4 Depomed Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.2.5 Depomed Recent Development10.3 Novartis 10.3.1 Novartis Company Details 10.3.2 Novartis Business Overview and Its Total Revenue 10.3.3 Novartis Peripheral Neuritis Treatment Introduction 10.3.4 Novartis Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.3.5 Novartis Recent Development10.4 Biogen 10.4.1 Biogen Company Details 10.4.2 Biogen Business Overview and Its Total Revenue 10.4.3 Biogen Peripheral Neuritis Treatment Introduction 10.4.4 Biogen Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.4.5 Biogen Recent Development10.5 GlaxoSmithKline 10.5.1 GlaxoSmithKline Company Details 10.5.2 GlaxoSmithKline Business Overview and Its Total Revenue 10.5.3 GlaxoSmithKline Peripheral Neuritis Treatment Introduction 10.5.4 GlaxoSmithKline Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.5.5 GlaxoSmithKline Recent Development10.6 Sanofi 10.6.1 Sanofi Company Details 10.6.2 Sanofi Business Overview and Its Total Revenue 10.6.3 Sanofi Peripheral Neuritis Treatment Introduction 10.6.4 Sanofi Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.6.5 Sanofi Recent Development10.7 Eli Lilly and Company 10.7.1 Eli Lilly and Company Company Details 10.7.2 Eli Lilly and Company Business Overview and Its Total Revenue 10.7.3 Eli Lilly and Company Peripheral Neuritis Treatment Introduction 10.7.4 Eli Lilly and Company Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.7.5 Eli Lilly and Company Recent Development10.8 Bristol-Myers Squibb 10.8.1 Bristol-Myers Squibb Company Details 10.8.2 Bristol-Myers Squibb Business Overview and Its Total Revenue 10.8.3 Bristol-Myers Squibb Peripheral Neuritis Treatment Introduction 10.8.4 Bristol-Myers Squibb Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.8.5 Bristol-Myers Squibb Recent Development10.9 Baxter Healthcare 10.9.1 Baxter Healthcare Company Details 10.9.2 Baxter Healthcare Business Overview and Its Total Revenue 10.9.3 Baxter Healthcare Peripheral Neuritis Treatment Introduction 10.9.4 Baxter Healthcare Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.9.5 Baxter Healthcare Recent Development10.10 Johnson & Johnson 10.10.1 Johnson & Johnson Company Details 10.10.2 Johnson & Johnson Business Overview and Its Total Revenue 10.10.3 Johnson & Johnson Peripheral Neuritis Treatment Introduction 10.10.4 Johnson & Johnson Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.10.5 Johnson & Johnson Recent Development10.11 Teva Pharmaceuticals 10.11.1 Teva Pharmaceuticals Company Details 10.11.2 Teva Pharmaceuticals Business Overview and Its Total Revenue 10.11.3 Teva Pharmaceuticals Peripheral Neuritis Treatment Introduction 10.11.4 Teva Pharmaceuticals Revenue in Peripheral Neuritis Treatment Business (2015-2020) 10.11.5 Teva Pharmaceuticals Recent Development 11Analysts Viewpoints/Conclusions 12Appendix12.1 Research Methodology 12.1.1 Methodology/Research Approach 12.1.2 Data Source12.2 Disclaimer12.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original:
Peripheral Neuritis Treatment Market to Grow Significantly With Increasing Advancements in Technology, Says QYR - Cole of Duty

BALTIMORE (WJZ) A stem cell therapy trial for the most critically ill coronavirus patients is underway in Maryland.

Researchers at the University of Maryland School of Medicine are trying to save the maximum number of patients who are significantly sickened by the virus and reduce the mortality rate.

Thanks to a sponsorship by Australian regenerative medicine company Mesoblast, the stem cell therapy trial is underway at several sites across the U.S., including in Maryland.

The therapy involves 300 people hospitalized with COVID-19 with moderate to severe acute respiratory distress syndrome.

These are patients that are intubated, requiring great support for their lung function, Dr. Sunjay Kaushal with the University of Maryland said.

CORONAVIRUS RESOURCES:

COVID-19 patients often become very ill from an escalated immune response referred to as a cytokine storm, which creates high levels of inflammation that can be fatal. The experimental stem cell therapy called remestemcel-L, which has been developed for various inflammatory conditions like what is being seen with the coronavirus, aims to block or mitigate that response, Kaushal said.

Were trying to extrapolate from what they have been shown to be efficacious in trying to treat before and trying to use that type of therapy now for COVID-19 patients, he said.

Once the final results from the trial are available, which could take between six and eight months, researchers hope to reach even more patients.

Were excited, weve seen some early signs that these cells may be efficacious, Kaushal said.

Ultimately, their hope is to provide a new treatment for those suffering from the worst cases of COVID-19.

Were hoping we can save a lot of patients lives, Kaushal said.

For the latest information on coronavirus go to the Maryland Health Departments website or call 211. You can find all of WJZs coverage on coronavirus in Maryland here.

Visit link:
Stem Cell Therapy Designed To Treat Severely Ill Coronavirus Patients Being Tested In Maryland - CBS Baltimore

Stem Cell Therapy for Kidney Disease (888) 988-0515

SAN DIEGO (PRWEB) June 09, 2020

R3 Stem Cell International, the leading regenerative clinic in Mexico, announced a new stem cell program for kidney disease. The program involves upwards of 200 million live stem cells and starts at only $8975.

R3's world renowned center has helped hundreds of patients over the past years for such conditions as kidney failure, autoimmune disease, COPD, stroke, diabetes, arthritis, ALS, MS and many more ailments. While stem cell therapy for kidney disease in Mexico works fantastic on a single visit, the new program provides significantly increased cell counts.

According to R3 International Medical Director Ramon De La Puerta MD, "We have seen so many patients avoid dialysis and get back to desired activities with our newest protocol. The key is the large numbers of quality stem cells and exosomes provided during treatment, and it's extremely affordable!"

The two options for the kidney failure stem cell treatment in Mexico include several therapies in a five day visit or four visits over a one year period. The total stem cell counts for either option range from 150 to 200 million.

The treatment programs start at only $8975, with interested patients starting with a free phone consultation. The experienced, licensed, stem cell doctor will review any medical records and provide a recommendation.

According to R3 CEO David Greene, MD, MBA, "Achieving treatment in the US with this many stem cells would be prohibitively expensive. So I created R3 International where treatment is not only affordable, but amazingly safe and effective. The biologics our Center uses undergo quality assurance testing that actually exceeds FDA standards in the US!"

R3 Stem Cell International assists patients with travel logistics, and offers concierge escorted transportation from San Diego to the treatment center. Phone consultations are free, and the stem cell biologics have a perfect safety record. Call (888) 988-0515 to set up the consultation, and visit https://stemcelltreatmentclinic.com/the-process/ to see how the process works to receive treatment.

Share article on social media or email:

Continued here:
R3 International Offering New Stem Cell Therapy Program for Kidney Disease in Mexico - PR Web

Global Stem Cell Therapy Market 2020-2025 is one of the most comprehensive and important additions to Adroit Market Research archive of market research studies. It offers detailed research and analysis of key aspects of the global market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Stem Cell Therapy market. The report also analyzes factors such as drivers, restraints, opportunities, and trends affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides particulars of the competitive landscape for market leaders.

Get sample copy of Stem Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/691

Stem Cell Therapy market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Stem Cell Therapy Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2020-2025.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

The report includes a detailed segmentation study of the global Stem Cell Therapy market, where all of the segments are analyzed in terms of market growth, share, growth rate, and other vital factors. It also provides the attractiveness index of segments so that players can be informed about lucrative revenue pockets of the global Stem Cell Therapy market. The extensive evaluation of segments provided in the report will help you to direct your investments, strategies, and teams to focus on the right areas of the global Stem Cell Therapy market.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Geographically, global Stem Cell Therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Among these regions, North America has been the dominating region the global Stem Cell Therapy market with highest percentage share. Further, North America region is expected to witness a robust growth during the forecast period. Moreover, Asia Pacific region is anticipated to be fastest growing market for Stem Cell Therapy during the forecast period.

Finally, researchers throw light on the pinpoint analysis of Global Stem Cell Therapy market dynamics. It also measures the sustainable trends and platforms which are the basic roots behind the market growth. The degree of competition is also measured in the research report. With the help of SWOT and Porters five analysis, the market has been deeply analyzed. It also helps to address the risk and challenges in front of the businesses. Furthermore, it offers extensive research on sales approaches.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See original here:
Stem Cell Therapy Market Size, Share 2020 Globally Industry Demand, Trends, Regional Overview, Top Manufacture, Business Growth and Forecast to 2025 -...

A new market report by Market Research Intellect on the Stem Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Stem Cell Therapy sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=285194&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Stem Cell Therapy manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Stem Cell Therapy Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=285194&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Stem Cell Therapy. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=285194&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Stem Cell Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

The rest is here:
Stem Cell Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

The Stem Cell Therapy Market report has been evaluated with respect to vital aspects such as Industry Strategies, Evolving Technology, Growth rate, Key Companies, Business Competitors, and Forecast till 2025. Substantial details highlighting the importance of the most significant sectors of this business are included in the study.

The Stem Cell Therapy Market is anticipated to record its name in the billion-dollar space within seven years, by exceeding revenue of US$ 15 billion by 2025, with an anticipated CAGR of 10.2% through 2025.

Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/3331

The Stem Cell Therapy Market report delivers a concise analysis pertaining to the competitive landscape of this industry. All the vital information with regards to this parameter have been covered in the report in a systematic manner. The overall summary has been included after conducting a detailed analysis of the driving parameters, the factors that may hamper the market growth, as well as the growth prospects that this business space has in the future.

Market Segmentation:

Know about Market growth in New Research and its Top growing factors by Key Companies like

Astellas Pharma Inc, Capricor Therapeutics, Cellectis, Cellular Dynamics, Celyad, CESCA Therapeutic, DiscGenics, Gamida Cell, Mesoblast Ltd, Novadip Biosciences, OxStem, ReNeuron Group plc, Takeda Pharmaceuticals

Comprehensive Review of Market Growth, Applications, and Future Prospects

The Regional Evaluation Ensures

Make an inquiry for purchasing this [emailprotected] https://www.gminsights.com/inquiry-before-buying/3331

The Stem Cell Therapy Market research report presents a detailed outline of Stem Cell Therapy Market this is mainly inclusive of the generic market definitions, the numerous segmentations, as well as the application landscape. The report outlines a detailed examination of the industry vendors from a regional and global perspective.

An exhaustive brief of the various forecast trends and demand till the year 2025 has been given in the report. The study is inclusive of information pertaining to the numerous firms that form a part of the competitive terrain of this business sphere. Also, the report contains, in exclusive detail, information on the many innovations in this sector, technologies adopted, and also many other factors impacting the product demand.

Report Growth Drivers

Request for discount @ https://www.gminsights.com/request-discount/3331

The Stem Cell Therapy Market Report Includes

See the original post:
Stem Cell Therapy Market Comprehensive Analysis, Growth Forecast From 2019 To 2025 - Cole of Duty

Boston-based hearing loss gene therapy biotech Akouos is gunning for a $100 million IPO amid a near invulnerable market for public-seeking biotechs.

This comes just three months after it grabbed a $105 million series B funding round from a host of big names including the likes of 5AM Ventures, New Enterprise Associates, Novartis Venture Fund and Partners Innovation Fund as well as new participants Cowen Healthcare Investments, Polaris and Pivotal bioVenture Partners, which led the round.

Back in March, and in conjunction with its raise, the biotech also appointed Vertex and Biogen research veteran Vicki Sato, Ph.D., and Pivotal bioVenture Partners Managing Partner Heather Preston, M.D., to its board.

Brand Revitalization with RP Scherer Softgel Solutions for Analgesics

A global consumer healthcare company needed to revitalize one of their leading OTC brands competing in the analgesic category. In a series of innovation sessions, Catalent RP Scherer softgel capsules were quickly identified as the ideal solution to drive incremental growth. With a highly-successful launch and halo growth for the entire brand, the new line extension increased the brands overall market share.

Now, in the middle of a pandemic, it wants to follow many other biotechs and gun for an IPO worth $100 million to help push its lead program AK-OTOF into the clinic.

The biotech is targeting monogenic forms of sensorineural hearing loss. These forms arise when changes to single genes cause sensory cells or nerve fibers in the inner ear to malfunction.

In its SEC-1 filing, the biotech said that, after speaking with the FDA: We are designing our phase 1/2 trial to include auditory brainstem response (ABR) as an efficacy endpoint. We believe that this will enable us to quickly determine a clinical response and potentially result in rapid advancement towards a pivotal trial.

We plan to submit an investigational new drug application for AK-OTOF for OTOF-mediated hearing loss to the FDA in 2021, and we expect to report preliminary clinical data in 2022.

As it sees it, there is a great hope for gene therapy for hearing loss, but the issue is delivery: We believe genetic medicine development for hearing disorders has been hindered by the unique anatomical delivery challenges of the inner ear, it said in its filing.

To get around this, the biotech has combined a proprietary vector library of syntheticadeno-associated viruses (AAVs) that recreates the evolutionary lineage of current naturally occurring viruses, known as ancestral AAV, or AAVAnc, and a new, what it says is a minimally invasive delivery approach, that allows it to use AAV-enabled multimodal capabilities, including viral delivery, to the target cell population where the full-length transgene is split into two vectors, known as a dual vector method.

It plans to file on the Nasdaq under the ticker "AKUS."

Go here to see the original:
3 months after its B round, Akouos files an IPO to the tune of $100M - FierceBiotech

WALTHAM, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies, announced today the appointment of Elliott Sigal, M.D., Ph.D., to the companys Board of Directors. Dr. Sigal has more than 25 years of leadership experience in the biopharmaceutical industry and is the former Chief Scientific Officer and President of R&D for Bristol Myers Squibb.

As a trailblazer in the biopharmaceutical industry, Dr. Sigal has demonstrated a track record of bringing transformative medicines to patients, said Rick Modi, Chief Executive Officer at Affinia Therapeutics. We look forward to the counsel he will provide to advance our platform and investigational product candidates toward the clinic and the patients who need them most.

Dr. Sigal is a former member of the Board of Directors of Spark Therapeutics. During his tenure from 2014 to 2019, the companys lead product, LUXTURNA was approved as the first AAV gene therapy in the United States. The company was acquired by Roche in 2019.

Prior to Spark Therapeutics, Dr. Sigal was an Executive Vice President and Director of Bristol Myers Squibb. While at BMS, he led the team that established BMS at the forefront of immuno-oncology which is revolutionizing the treatment of cancer and brought fourteen new medicines to market for patients with devastating diseases in areas including oncology, hematology, cardiovascular disease, hepatitis, rheumatoid arthritis and neuropsychiatry. Dr. Sigal was instrumental in increasing R&D productivity and developing the companys strategy in biologics. In 2012, he was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence.

Affinia Therapeutics is setting a new standard in gene therapy, said Dr. Elliott Sigal. I am pleased to join the companys board at such an exciting time as they pioneer and design vectors and genetic medicines to transform the applicability of gene therapies for patients in need.

Dr. Sigal received his medical degree from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at the University of California, San Francisco (UCSF). He also holds a Bachelor of Science, Master of Science and Ph.D. in Industrial Engineering from Purdue University. Dr. Sigal currently serves as a senior advisor to the healthcare team of New Enterprise Associates and consults for select biotechnology companies including Amgen. He is co-chair of the Scientific Advisory Board of Amgen and is a member of the Scientific Steering Committee of the Sean Parker Institute for Cancer Immunotherapy. He is also a member of the Board of Directors for the biotechnology companies Adaptimmune and Surface Oncology. Dr. Sigal joined BMS in 1997 and held roles in both discovery and development before ascending to Chief Scientific Officer and President of R&D. Positions prior to BMS included a faculty appointment at UCSF, senior executive roles at Syntex/Roche and CEO of the genomics firm, Mercator Genetics.

Dr. Sigal joins Affinia Therapeutics board which includes Dave Grayzel, M.D., Partner, Atlas Venture; Ed Mathers, General Partner, New Enterprise Associates; Luk Vandenberghe, Ph.D., Associate Professor at Mass. Eye and Ear and Harvard Medical School; Rick Modi, Chief Executive Officer, Affinia Therapeutics; Robert Weisskoff, Ph.D., Partner, F-Prime Capital; and Sean Nolan, Chairman of the Board of Directors at Affinia Therapeutics.

About Affinia Therapeutics

At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need. http://www.affiniatx.com.

Affinia Therapeutics Contacts

Investors: investors@affiniatx.com

Media: media@affiniatx.com

Read this article:
Affinia Therapeutics Announces Appointment of Elliott Sigal, MD, Ph.D. to the Company's Board of Directors - GlobeNewswire

DetailsCategory: DNA RNA and CellsPublished on Monday, 08 June 2020 18:17Hits: 336

- In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase in transduction and expression when compared with the low-dose cohort, with a mean of 72% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 50% measure for success ---- A mean signal intensity of 73% in the high-dose group was observed compared to normal control ---- A mean beta-sarcoglycan expression of 62% as measured by Western blot was observed in the high-dose cohort compared to normal control ---- An 89% mean reduction of creatine kinase (CK) from baseline was observed in the high-dose cohort ---- Continued functional improvement was observed in the low-dose cohort at one year --

CAMBRIDGE, MA, USA I June 08, 2020 I Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from a study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E). Results included safety and expression results from three clinical trial participants in the high-dose cohort measured at 60 days, and one-year functional data from three clinical trial participants in the low-dose cohort. SRP-9003 is in development for the treatment of LGMD2E (also known as beta-sarcoglycanopathy and LGMDR4), a devastating monogenic neuromuscular disease caused by a lack of beta-sarcoglycan (beta-SG) proteins. SRP-9003 is a gene construct that transduces skeletal and cardiac muscle, delivering a gene that codes for the full-length beta-sarcoglycan protein, the absence of which is the sole cause of progressive degeneration and a shortened lifespan characterized by the disease.

We were very encouraged by the previously reported results from our first cohort of patients treated with a lower dose of SRP-9003, including impressive expression, good tolerability, and positive functional signals, which continue impressively at one year. We are excited to have been able to achieve even more impressive expression and other biomarkers in our higher-dose cohort for SRP-9003, along with good tolerability. The SRP-9003 gene construct, vector and promoter were designed with the goal of robustly delivering to skeletal and cardiac muscles a gene coding for the missing beta-sarcoglycan protein that causes LGMD2E. These data support the conclusion that the therapy is achieving its intended purpose, driving robust expression in the muscles where it is needed, said Doug Ingram, President and CEO, Sarepta. SRP-9003 employs the same vector, AAVrh74, and same promoter, MHCK7, as SRP-9001, our therapy in development to treat Duchenne muscular dystrophy. And Cohort 2 received a similar dose as our ongoing SRP-9001 studies for Duchenne. The safety and efficacy results with these two doses of SRP-9003 provide us with additional experience and confidence with the rh74 vector and the MHCK7 promoter as we select the dose for the pivotal trial of SRP-9003 and work to quickly develop this therapy for patients who currently have no treatment options.

The SRP-9003 study has two cohorts, each studying a different dose-per-kilogram based on the weight of the patient. Three participants in the low-dose cohort (Cohort 1) were treated with a one-time infusion of SRP-9003 dosed at 5x1013vg/kg and an additional three participants in the high-dose cohort (Cohort 2) received a one-time infusion dosed at 2x1014vg/kg. The six participants were between the ages of 4 and 13. Post-treatment biopsies were taken at 60 days. Sarepta previously shared data from Cohort 1 in 2019, including positive and robust expression and biomarker data and positive 9-month functional results.

Preliminary results from Cohort 2 (n=3) are as follows:

In Cohort 1 (low dose), at one year all three participants continued to show improvements from baseline across all functional measures, including the North Star Assessment for Limb-Girdle Muscular Dystrophies, time-to-rise, four-stair climb, 100-meter walk test and 10-meter walk test. These results are distinctly different from what an age-matched, natural history group would predict. There have been no new drug-related safety signals observed since the 9-month update, and no decreases in platelet counts outside of the normal range or signs of complement activation were observed.

LGMD2E is a devastating neuromuscular disease that causes significant disability in the children we see and currently lacks treatment options beyond tailored physical therapy, said Jerry Mendell, M.D., principal investigator at the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Childrens Hospital and lead investigator for the study. We are pleased that these data show robust expression, similar to what we observed in the micro-dystrophin program, for the protein that is missing in children with LGMD2E, and remain hopeful that this brings us one step closer to a therapy that can help improve both prognosis and quality of life.

About SRP-9003 and the studySRP-9003 uses the AAVrh74 vector, which is designed to be systemically and robustly delivered to skeletal, diaphragm and cardiac muscle, making it an ideal candidate to treat peripheral neuromuscular diseases. AAVrh74 has lower immunogenicity rates than reported with other human AAV vectors. The MHCK7 promoter has been chosen for its ability to robustly express in the heart, which is critically important for patients with limb-girdle muscular dystrophy Type 2E (LGMD2E), also known as beta-sarcoglycanopathy and LGMDR4, many of whom die from pulmonary or cardiac complications.

This first-in-human study is evaluating a single intravenous infusion of SRP-9003 among children with LGMD2E between the ages of four and 15 years with significant symptoms of disease. Sarepta has exclusive rights to the LGMD2E gene therapy program initially developed at the Abigail Wexner Research Institute at Nationwide Childrens Hospital.

About Limb-Girdle Muscular DystrophyLimb-girdle muscular dystrophies are genetic diseases that cause progressive, debilitating weakness and wasting that begin in muscles around the hips and shoulders before progressing to muscles in the arms and legs.

Patients with limb-girdle muscular dystrophy Type 2E (LGMD2E) begin showing neuromuscular symptoms such as difficulty running, jumping and climbing stairs before age 10. The disease, which is an autosomal recessive subtype of LGMD, progresses to loss of ambulation in the teen years and often leads to early mortality. There is currently no treatment or cure for LGMD2E.

Sarepta has five LGMD gene therapy programs in development, including subtypes for LGMD2E, LGMD2D, LGMD2C, LGMD2B and LGMD2L, and holds an option for a sixth program for LGMD2A.

AboutSarepta TherapeuticsAt Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Companys programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visitwww.sarepta.comor follow us onTwitter,LinkedIn,InstagramandFacebook.

SOURCE: Sarepta Therapeutics

See more here:
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy...

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (Aerpio) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader (KOL) call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time.

The call will feature presentations by Dr. Paul Kaufman M.D. (University of Wisconsin) and Dr. Janey Wiggs, M.D., Ph.D. (Massachusetts Eye and Ear Infirmary and Harvard Medical School), who will discuss the current glaucoma treatment landscape and unmet medical needs, as well as the role of the Tie2 receptor in maintaining intraocular pressure. Drs. Kaufman and Wiggs will be available to answer questions at the conclusion of the event.

Aerpio's management team will also discuss its pipeline candidate, razuprotafib (formerly AKB-9778), for treating patients with glaucoma. Razuprotafib is a small molecule inhibitor that restores Tie2 activation in Schlemms canal and lowers intraocular eye pressure (IOP) via decreasing resistance to outflow from the eye. Razuprotafib has been formulated as a once or twice-daily topical eye drop and is entering a Phase 2 clinical trial in Q3:20, with top line data expected in Q1:21.

Aerpio recently announced positive and statistically significant intraocular eye pressure (IOP) reduction in a Phase 1b trial of 43 glaucoma patients, when razuprotafib was added to prostaglandin treatment. This data set is summarized here.

Paul Kaufman, M.D. is the Ernst H. Brny Emeritus Professor of Ocular Pharmacology and past Chair of the Department of Ophthalmology & Visual Sciences at the University of Wisconsin School of Medicine and Public Health, in Madison, Wisconsin. He is a physician-scientist, specializing in glaucoma and studying the mechanisms of aqueous humor formation and drainage, and the age-related loss of near vision. Dr Kaufman is a past President and past Executive Vice President of the Association for Research in Vision and Ophthalmology (ARVO), past President of the International Society for Eye Research (ISER), and has served on the US National Advisory Eye Council and numerous foundation and corporate scientific advisory boards. He has had continuous research funding from the US National Eye Institute for 40 years and from numerous private foundations, has authored over 375 original scientific articles and 75 book chapters, co-edited several textbooks including the most recent editions of Adlers Physiology of the Eye, and received numerous honors and awards including the Friedenwald Award from ARVO and the Balazs Prize from ISER. He was Editor-in-Chief of Investigative Ophthalmology & Visual Science from 2008 through 2012. Dr. Kaufman also holds an honorary Doctor of Medicine degree from Uppsala University in Sweden, where he was a post-doctoral research fellow.

Janey L. Wiggs, M.D., Ph.D. is a physician-scientist at the Massachusetts Eye and Ear Infirmary and Harvard Medical School. She is currently the Paul Austin Chandler Professor of Ophthalmology and is the Vice Chair for Clinical Research in Ophthalmology at Harvard Medical School. She also directs the CLIA-certified genetic testing laboratory at the Massachusetts Eye and Ear Infirmary and is a co-director of the Ocular Genomics Institute and co-director of the Glaucoma Center of Excellence. Dr. Wiggs received her B.A. and Ph.D. degrees in biochemistry from the University of California at Berkeley and her M.D. degree from Harvard Medical School. She did post-doctoral training in molecular genetics under the direction of Dr. Ted Dryja. Dr. Wiggs completed the ophthalmology residency at the Massachusetts Eye and Ear Infirmary and received fellowship training in glaucoma and also in medical genetics and is certified by the both the American Board of Ophthalmology and the American Board of Medical Genetics. Dr. Wiggs research program is focused on the discovery and characterization of genetic factors that contribute to the blinding eye disease glaucoma and is funded by the National Eye Institute (NEI) as well as other nonprofit foundations. She is investigating the genetic etiologies of both early-onset and adult forms of glaucoma and is the PI of the NEIGHBORHOOD consortium for gene discovery in primary open angle glaucoma and is a founding member of the International Glaucoma Genetics Consortium (IGGC). She has also participated in research programs funded by the US-INDO joint working group (NEI) and the NEI eyeGENE consortium. Dr. Wiggs was the inaugural chair of the Genetics Group for ARVO and is an ARVO gold fellow. She currently serves on the editorial boards of IOVS, JAMA Ophthalmology, Molecular Vision, Journal of Glaucoma, and Annual Reviews in Vision Science. She is a member of the scientific advisory boards for the Glaucoma Research Foundation, Research to Prevent Blindness and the Glaucoma Foundation, and is a past member of the Advisory Council of the National Eye Institute. She has received the Heed Award, the Heed/Knapp Award, the Research to Prevent Blindness Scholar Award, the AAO Honor Award, the Lew Wasserman Merit Award, the Alcon Research Award, the David L. Epstein award from the ARVO Foundation and was a winner of the NEI Audacious Goal competition. She is an elected member of the Glaucoma Research Society, the American Ophthalmological Society, the Academia Ophthalmologica Internationalis and the National Academy of Medicine.

About RazuprotafibRazuprotafib binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity contributes to vascular instability in many diseases including diabetes and more recently has been shown to contribute to the development of increased IOP and glaucoma. Razuprotafib activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist) and may be the most efficient pharmacologic approach to maintain normal Tie2 activation. Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy.

About Aerpio PharmaceuticalsAerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemms canal, a critical component of the conventional outflow tract. The Companys lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP), is being developed as a potential treatment for open angle glaucoma, and the Company intends to investigate the therapeutic potential of razuprotafib in other indications. The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema (DME). The Companys third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924s exclusive licensor, Gossamer Bio, Inc. (Nasdaq: GOSS). For more information, please visit http://www.aerpio.com.

Forward Looking StatementsThis press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the Companys product candidates, including razuprotafib, ARP-1536 and the bispecific antibody asset, the clinical development plan therefor and the therapeutic potential thereof, the Companys plans and expectations with respect to razuprotafib and the development therefor and therapeutic potential thereof in addressing COVID-19 and the intended benefits from the Companys collaboration with Gossamer Bio for GB004, including the continued development of GB004 and the milestone and royalty payments related to the collaboration. Actual results could differ from those projected in any forward-looking statements due to several risk factors. Such factors include, among others, the continued development of GB004 and maintaining and deriving the intended benefits of the Companys collaboration with Gossamer Bio; ability to continue to develop razuprotafib or other product candidates, including in indications related to COVID-19; the inherent uncertainties associated with the drug development process, including uncertainties in regulatory interactions, the design of planned or future clinical trials, commencing clinical trials and enrollment of patients in clinical trials; obtaining any necessary regulatory clearances in order to commence and conduct planned or future clinical trials; the impact of the ongoing COVID-19 pandemic on the Companys business operations, including research and development efforts and the ability of the Company to commence, conduct and complete its planned clinical activities; and competition in the industry in which the Company operates and overall market conditions; and the additional factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q and our other subsequent filings with the SEC.

These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the Company files with the SEC available at http://www.sec.gov.

Investors & Media:Gina MarekVP Financegmarek@aerpio.comOrInvestors:Irina KofflerLifeSci Advisorsikoffler@lifesciadvisors.com

See the original post:
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma - GlobeNewswire

While most people who contract the new coronavirus develop a mild case of Covid-19, for some the disease is deadlyand researchers are exploring whether a person's DNA may play a role in determining the disease's severity.

How Dignity Health keeps patients connected to telegeneticsduring and beyond Covid-19

Researchers already have determined that a person's age and whether they have certain underlying health conditions can affect their risk of developing a severe case of Covid-19, the disease caused by the new coronavirus. But now, some research suggests a person's blood type may be another factor in whether they have a higher risk of developing a severe case of the disease.

For example, a preprint study published Tuesday that has not been peer-reviewed examined blood samples from 1,610 Covid-19 patients who developed severe cases of Covid-19, which the researchers classified as needing oxygen or a ventilator as part of their treatment. The researchers sequenced part of each those patients' genomes, and then performed the same analysis on samples from 2,205 blood donors who did not have Covid-19 and compared the results.

The researchers found that many of the patients who had severe cases of Covid-19 possessed the same variant on a gene that determines a person's blood type. Specifically, the researchers found that having blood type A was linked with a 50% increase in the likelihood a patient would develop a severe case of Covid-19.

According to the New York Times, a separate preprint study conducted by researchers in China that hasn't yet been peer-reviewed found similar results. The study found that, out of 2,173 Covid-19 patients with different blood types, blood type A was associated with a higher risk of death from Covid-19 when compared with other blood types. The study also found that people with blood type A appeared more likely to contract the new coronavirus, whereas those with blood type O appeared to be the least likely to contract the virus.

Andre Franke, a molecular geneticist at the University of Kiel in Germany, who led the first study said he and his colleagues also identified another locus on Chromosome 3 that appeared to be linked with Covid-19. However, the researchers noted that locus hosts six different genes, and they've yet to determine which of those genes influences how Covid-19 develops.

Despite the findings, Franke said researchers are still unsure exactly how a person's blood type plays a part in how Covid-19 affects them. "That is haunting me, quite honestly," he said.

Franke said the locus that hosts the blood-type gene also contains a portion of a person's DNA that controls a gene that makes a protein that generates robust immune responses, the Times reports. According to the Times, researchers and providers have found that the new coronavirus can trigger a so-called "cytokine storm" in some patients, which occurs when a patient's immune system overreacts to a pathogen and damages a patient's organs, and it's "theoretically possible that genetic variations influence that response."

For a separate study published last month in Cell, researchers looked into how the new coronavirus affects human cells and found that, within three days of infection, the virus activates genes in the cells that produce cytokine proteins, which are the proteins that can cause cytokine storm. At the same time, the virus blocks genes in the cells that produce interferons that could constrain the virus' replicationsomething most other viruses don't do, according to Benjamin tenOever of the Icahn School of Medicine at Mount Sinai, who co-authored the study. "It's something I have never seen in my 20 years of" studying viruses, he said.

tenOever explained that, without interferons, "there is nothing to stop the virus from replicating and festering in the lungs forever."

According to STAT News, the researchers' findings could help scientists identify treatments for Covid-19. For instance, Vineet Menachery from the University of Texas Medical Branch said providing high-risk patients with interferons could potentially "allow treated cells to fend off the virus better and limit its spread."

But more research on how genetic variants might affect Covid-19 are needed, according to Jonathan Sebat, a geneticist at the University of California-San Diego who was not involved in the studies. According to Sebat, previous studies attempting to identify variances in genetic loci that are significantly more common in sick people than healthy people have failed, meaning it's possible that the variants identified in the recent studies may not play as much as a role as in how Covid-19 develops as the new findings may imply (Zimmer, New York Times, 6/3; Begley, STAT News, 5/21; Mangin, Scientific American, 4/30).

Follow this link:
What's your blood type? The answer could affect your risk from Covid-19. - The Daily Briefing

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics is launching to create the next generation of regenerative medicines to restore hope for people affected by CNS disorders. The company has completed a $76 million Series B fundraising co-led by ARCH Venture Partners and Cowen Healthcare Investments, with participation from BVF Partners L.P., Biogen, Bristol Myers Squibb, Pfizer Ventures, Invus, Section 32, Samsara BioCapital and Alexandria Venture Investments. Proceeds will be used to advance Autobahns lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN), a rare genetic disorder, and a portfolio of transformational CNS programs leveraging the companys brain-targeting chemistry platform.

Autobahn is harnessing the regenerative power of the human body to treat both rare and prevalent CNS disorders. We are coupling our deep knowledge of thyroid hormone biology and remyelination with our brain-targeting chemistry platform to restore the brain to a healthier state, said Kevin Finney, chairman and chief executive officer of Autobahn. We stand well-positioned to advance our pipeline with funding from the highest quality investors and pharmaceutical leaders who share our mission of improving life health for people affected by these conditions.

Innovating Treatments for CNS Disorders

Autobahns scientific approach is based on the well-established role that thyroid hormone plays in the production of myelin, the protective sheath that forms around nerves. The degeneration of myelin is associated with many CNS disorders, including MS. Autobahn is developing small molecule, thyroid hormone receptor beta agonists designed to stimulate remyelination and address the progressive nature of MS and other diseases that result from demyelination. The companys strategy leverages validated human biology to de-risk and accelerate its development programs, a brain-targeting chemistry platform to maximize exposure selectively in the brain, and biomarker-driven development to establish on-target activity and proof-of-mechanism early in development.

We believe Autobahn has the insights and expertise to turn this world-class research into important medicines for patients. The work pioneered by Dr. Tom Scanlan of Oregon Health & Science University served as a strong base on which to add a highly talented team of researchers and clinical innovators to create Autobahn, said Kristina Burow, managing director with ARCH Venture Partners. We are proud to be working alongside the company to harness the transformative potential of Autobahns remyelinating therapies.

Leadership Team with Proven Track Record

Autobahn has built a team of experts in thyromimetics, drug discovery and development, clinical operations, and corporate and business development:

Autobahn is developing a differentiated portfolio of CNS therapies, backed by validated science and led by proven scientific and business leaders, said Tim Anderson, managing director of Cowen Healthcare Investments. Investing in innovative life sciences companies is at the heart of Cowen Healthcare Investments, and we are excited to join the Autobahn team to help develop products that can fundamentally change the way people with CNS disorders are treated.

Expert Board of Directors

Autobahn has established a board of directors with significant experience in company formation and scientific innovation. Directors include:

Autobahn benefits from the winning combination of validated human biology supporting its therapeutic hypothesis, clever chemistry enabling tissue-selective CNS delivery of compounds and an exceptional team to drive it forward, added Dr. Cravatt. I am highly confident in our potential to create the next generation of regenerative medicines for the brain.

About Autobahn Therapeutics

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The companys pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. For more information, visit http://www.autobahntx.com.

Read more:
Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders - Business Wire